ArticleScientific reports2026
Linking lipid profile alterations to antibiotic tolerance and natural product synergy in drug-resistant Mycobacterium tuberculosis clinical isolates.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Despite global control efforts, tuberculosis remains the leading infectious cause of death, with rising incidence, pediatric cases, and drug-resistant strains posing major public health challenges. Mycobacteria, including Mycobacterium tuberculosis, possess a lipid-rich, dual-membrane cell envelope that contributes to their impermeability, drug resistance, and unique pathogenic mechanisms. Some lipids play key roles in modulating host immune responses, enabling survival within macrophages, and promoting granuloma formation. Since it is known that lipid remodeling of the cell envelope is correlated with the antibiotics tolerance in mycobacteria we used liquid chromatography coupled to mass spectrometry to analyze the lipid profiles of M. tuberculosis clinical isolates with diverse drug-resistance characteristics in order to investigate if there is any link between Mtb lipids composition, its drugs susceptibility and the antimycobacterial activity of natural small molecules used in combination with first line antibiotics. The results showed that among cross combinations of antibiotics and natural products (piperine and thymoquinone) the potentiation of antimycobacterial activity was obtained in all strains only for rifampicin. Drug-resistant isolates presented the shift in glycerophospholipids building the inner membrane towards molecules with shorter acyl chains, but the decreased membrane hydrophobic thickness was compensated in some strains by increased membrane rigidity. The pXDR/XDR isolates accumulated mycobactins loaded iron and showed dysregulation in the production of phthiocerol/phthiodiolone dimycocerosates and triacylglycerols.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.